Abstract 1568P
Background
Lung cancer (LC) screening is an effective secondary preventive measure in decreasing LC mortality. Except for age and smoking history prediction models with additional variables were verified in different populations. In September 2020 the first pilot program for early detection of LC started in Vojvodina, Serbia. To increase LC positive findings we analyze characteristics of screening participants from September 2020 to April 2024.
Methods
Eligibility for LC screening is restricted to persons aged 50-74 years, with a smoking history of 30 pack-years, or 20 pack-years with additional risks; either active or quit smoking within the previous 10 years. Participants sign informed consent and fill out an online questionnaire with socio-demographic data (age, gender, marital, education, working status), smoking status (pack-years), exposure data (professional, tobacco exposure in childhood, in adulthood), BMI, alcohol consumption, symptoms of respiratory diseases, presence of chronic disease or cancer of other localization, and family history of LC. Screening results were reported by Lung RADS score (1 to 4). Differences between participants with positive (score 4) and negative or intermediate (score 1 to 3) results were analyzed.
Results
During the observed period, 61.3% (1690/2759) of screened were females. Positive screens were reported in 264(9.6%) of participants. Characteristics of participants divided by scores (4 vs score 1-3) showed differences in age (64.03±6.62 vs 61.54±6.71, p<0.001), BMI (25.35±3.87 vs 26.64±4.58, p<0.001), years of smoking (38.82±9.47 vs 37.01±8.60, p=0.001), pack-years (42.59±17.06 vs 39.49±16.20, p=0.003), appetite loss (11.4% vs 6.7%, p=0.005), and weight loss (14.4% vs 8.1%, p<0.001). Significant differences were observed between participants according to employment (p<0.001) and education level (p=0.022); retired (60.6% vs 44.3%) and finished primary school (14.0% vs 8.6%) were more common in score 4, while employed (43.2% vs 27.3%) and faculty education (23.7% vs 19.7%) in score 1-3.
Conclusions
Reaching more elderly and heavy smoker participants with lower BMI and lower education could increase the percentage of LC positive screening results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Pulmonary Diseases of Vojvodina.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1501P - Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care
Presenter: Luca Tontini
Session: Poster session 10
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10